[go: up one dir, main page]

ZA200801248B - PEG-IFN alpha and ribaviriin for HBV treatment - Google Patents

PEG-IFN alpha and ribaviriin for HBV treatment

Info

Publication number
ZA200801248B
ZA200801248B ZA200801248A ZA200801248A ZA200801248B ZA 200801248 B ZA200801248 B ZA 200801248B ZA 200801248 A ZA200801248 A ZA 200801248A ZA 200801248 A ZA200801248 A ZA 200801248A ZA 200801248 B ZA200801248 B ZA 200801248B
Authority
ZA
South Africa
Prior art keywords
ribaviriin
peg
ifn alpha
hbv treatment
hbv
Prior art date
Application number
ZA200801248A
Other languages
English (en)
Inventor
Janssen Henricus Leonardus Antonius
Popescu Matei
Pluck Nigel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200801248(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200801248B publication Critical patent/ZA200801248B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200801248A 2005-08-15 2008-02-05 PEG-IFN alpha and ribaviriin for HBV treatment ZA200801248B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107473 2005-08-15

Publications (1)

Publication Number Publication Date
ZA200801248B true ZA200801248B (en) 2008-11-26

Family

ID=37654895

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801248A ZA200801248B (en) 2005-08-15 2008-02-05 PEG-IFN alpha and ribaviriin for HBV treatment

Country Status (16)

Country Link
US (2) US20070071720A1 (ru)
EP (1) EP1917037A2 (ru)
JP (1) JP2009504706A (ru)
KR (1) KR20080027944A (ru)
CN (1) CN101242857A (ru)
AR (1) AR057746A1 (ru)
AU (1) AU2006281498A1 (ru)
BR (1) BRPI0614863A2 (ru)
CA (1) CA2617958A1 (ru)
IL (1) IL188962A0 (ru)
MX (1) MX2008002015A (ru)
NO (1) NO20080495L (ru)
RU (1) RU2008109649A (ru)
TW (1) TW200740455A (ru)
WO (1) WO2007020195A2 (ru)
ZA (1) ZA200801248B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
KR102012025B1 (ko) * 2012-08-13 2019-08-19 제이더블유크레아젠 주식회사 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질
AR112166A1 (es) * 2017-06-16 2019-09-25 Arbutus Biopharma Corp Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
US20230207064A1 (en) * 2021-12-29 2023-06-29 Illumina, Inc. Inter-model prediction score recalibration during training

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
ID29285A (id) * 1998-06-08 2001-08-16 Hoffmann La Roche PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS
US7186700B2 (en) * 2002-09-13 2007-03-06 Idenix Pharmaceuticals, Inc. β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
CN1809378B (zh) * 2002-11-18 2010-06-23 德西涅Rx制药公司 体内抑制病毒复制的方法
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2006010256A1 (en) * 2004-07-26 2006-02-02 Transition Therapeutics Inc. Compositions and methods comprising vitamin b12 and an impdh inhibitor for treating viral, inflammatory and proliferative diseases
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
WO2006050161A2 (en) * 2004-10-29 2006-05-11 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
AU2005302162A1 (en) * 2004-11-02 2006-05-11 Shire Llc Prodrugs of ribavirin with improved hepatic delivery
AU2006252718B2 (en) * 2005-05-31 2010-04-15 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis

Also Published As

Publication number Publication date
AU2006281498A1 (en) 2007-02-22
CN101242857A (zh) 2008-08-13
IL188962A0 (en) 2008-08-07
TW200740455A (en) 2007-11-01
MX2008002015A (es) 2008-03-25
US20080317714A1 (en) 2008-12-25
EP1917037A2 (en) 2008-05-07
JP2009504706A (ja) 2009-02-05
WO2007020195A2 (en) 2007-02-22
RU2008109649A (ru) 2009-09-27
NO20080495L (no) 2008-03-10
WO2007020195A3 (en) 2007-05-24
US20070071720A1 (en) 2007-03-29
KR20080027944A (ko) 2008-03-28
AR057746A1 (es) 2007-12-12
BRPI0614863A2 (pt) 2011-04-19
CA2617958A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
IL228770A0 (en) processes and intermediates
IL191072A0 (en) Therapeutic compositions and methods
PL1859004T3 (pl) Środki sieciujące kompozycję opracowania odwiertu oraz ich zastosowania
IL190745A0 (en) Microangiopathy treatment and prevention
PL1863899T3 (pl) Kompozycje do leczenia skóry
EP1960076A4 (en) TREATMENT OF HOSPITAL WASTE
GB0516069D0 (en) Pharmaceutical and use thereof
ZA200801248B (en) PEG-IFN alpha and ribaviriin for HBV treatment
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
GB2430002B (en) Well treatment
GB0415181D0 (en) Compounds for use in the treatment of infection
GB0523026D0 (en) Patient table
EP1928247A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
GB0511769D0 (en) Treatment
GB0426141D0 (en) Treatment
GB0424085D0 (en) Well treatment
GB0403696D0 (en) Process and composition
GB0523291D0 (en) Treatment table
GB0505203D0 (en) Skin composition treatment
GB0513680D0 (en) Biowaste treatment
GB0505383D0 (en) Diagnosis and treatment
GB0412411D0 (en) Treatment
GB0521290D0 (en) Pathogen diagnosis and treatment
GB0415318D0 (en) Medical treatment
GB0419703D0 (en) Medical treatment